(1 - 28 from 43
)
Eisai's Halaven receives FDA approval for treatment of patients with...
www.news-medical.net
Kenichi Nomoto, Ph.D., President, Oncology Product Creation Unit, ...
Eisai's Halavan misses endpoints in Phase III trial - PharmaTimes
www.pharmatimes.com
Eisai's breast cancer drug Halaven has failed to hit targets in a Phase III trial pitting its performance against Xeloda to gage its potential as a second-line...
Eisai Phase 3 trial of eribulin meets primary endpoint in patients...
www.news-medical.net
... sarcoma to demonstrate an overall survival benefit compared with an active agent," said Kenichi Nomoto, Ph.D., President, Oncology Product ...
Eisai and Merck Enter Collaboration to Explore Novel Combination...
www.eisai.com
Eisai's news release Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and...
sorted by relevance / date